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kidney disease. It also provides evidence against complete lossLocation of mutations within the PKD2 gene influences clinical
of function of the mutant PKD2 gene product.outcome.
Background. Since the cloning of the gene for autosomal
dominant polycystic kidney disease type 2 (PKD2), approxi-
mately 40 different mutations of that gene have been reported
With an estimated prevalence of 1 in 1000 [1, 2], au-to be associated with the disease. The relationship between
tosomal dominant polycystic kidney disease (ADPKD)the PKD2 genotype and phenotype, however, remains unclear.
Methods. Detailed clinical information was collected for is one of the most common, dominantly inherited disor-
PKD2 families in which the underlying mutation had been ders in humans. The disease is characterized by bilateral
identified. Logistic regression analysis was employed to assess multiple renal cysts, and it represents an important cause
the influence of age and sex on hypertension, hematuria, renal
of end-stage renal disease (ESRD). ADPKD is consid-calculi, and urinary tract infections, and a clinical phenotype
ered a multisystem disease, with cysts and connectivescore was computed. Patients were then grouped according
to the relative location of their mutation within the cDNA tissue abnormalities affecting many other organs [3].
sequence, and differences in the mean phenotypic score be- Common complications include hypertension, macro-
tween groups were tested for statistical significance by means scopic hematuria, urinary tract infection, renal calculi,
of a multiple pairwise t-test.
cardiac valve abnormalities, herniae of the anterior ab-Results. While phenotypic scores for each mutational group
dominal wall, and cerebral berry aneurysms.revealed a considerable degree of intragroup variability, the
variability in phenotypic scores was significantly higher between Molecular and linkage studies have revealed that
mutational groups than within groups. A group-wise compari- ADPKD is caused by mutations in at least three different
son of the mean phenotypic scores confirmed the observation genes, two of which have been cloned: polycystic kidney
of significant nonlinear variation in disease severity, with high-
disease type 1 (PKD1), located on chromosome 16p13.3and low-scoring mutational groups interspersed along the gene
[4–6], and polycystic kidney disease type 2 (PKD2), lo-sequence.
Conclusion. The identification of groups of mutations in the cated on chromosome 4q21-23 [7, 8]. At least one more
PKD2 gene, which differ significantly with respect to clinical gene responsible for ADPKD is thought to exist (PKD3),
outcome, is to our knowledge the first description of a geno- but its chromosomal location remains unknown [9–12].
type/phenotype correlation in autosomal dominant polycystic
Among Europeans, a PKD1 mutation underlies ADPKD
in approximately 85% of affected families, while PKD2
gene lesions have been considered to be responsible forKey words: polycystic kidney disease, autosomal dominant, PKD2,
phenotype, gene mutation, inherited kidney disease. most of the remaining 15% of cases [13]. It has become
clear that many individuals with PKD2 are unaware ofReceived for publication June 1, 1999
their condition [14, 15], making it likely that the trueand in revised form October 20, 1999
Accepted for publication November 1, 1999 proportion of PKD2 is substantially higher. This is sup-
ported by a recent report that found a high detection rateÓ 2000 by the International Society of Nephrology
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of PKD2 mutations in families with members developing failure was recorded for individuals on renal replacement
therapy. Where necessary, additional medical detailslate-onset ESRD at the age of 70 or older [16].
Since the PKD2 gene was cloned in 1996, approxi- were obtained from the attending doctor.
Deceased affected. Information collected on affectedmately 40 different PKD2 mutations have been reported
[7, 16–21]. As the location and nature of PKD2 mutations individuals who had died included their dates of birth
and death, mode of and age at diagnosis, known compli-may influence the clinical phenotype, a PKD2 study
group was established within the European Concerted cations, as well as cause of death. Whenever possible,
medical details were verified on the basis of medicalAction on PKD to collect clinical data from families
with an identified PKD2 mutation. The results of our records or death certificates. The age at onset of end-
stage renal failure was taken to be the age at which long-genotype-phenotype analysis are described herein.
term replacement therapy for renal function became nec-
essary.
METHODS
Families and clinical evaluation Mutational analysis
Most of the PKD2 mutations referred to in the presentSeven centers participated in the present study. PKD2
families from Spain, the Netherlands, the United King- study have been reported previously. Mutation analysis
in the remaining families was performed using estab-dom, Bulgaria, and Australia were selected on the basis
of the disease-causing mutation having been previously lished methodology [17, 18, 21]. The number of missense
mutations in this study was small (N 5 2) comparedidentified. Ethical approval was given by the various
ethical committees of the centers in Leiden, Santander, with truncating mutations (N 5 20). The mutations were
designated following recently published recommenda-Barcelona, Madrid, Melbourne, Cardiff, and London.
Informed consent was obtained from all individuals in- tions [23]. Nucleotides and codons were numbered with
the adenine of the initiator codon (ATG) counted asvolved. Within each PKD2 family, clinical information
was collected on the following three categories of number one. The latter corresponds to nucleotide num-
ber 67 of the original sequence report [7].ADPKD patients.
Newly diagnosed. These were previously undiagnosed
Statistical methodsfamily members who had their ADPKD status confirmed
by ultrasound examination, using previously established Linear logistic regression analysis as implemented in
the LOGISTIC procedure of the SAS/STATt softwarediagnostic criteria [22], DNA-linkage tests, or mutation
screening. The medical history of these individuals was package (version 6) was used to assess the influence of
age and sex on the prevalence of hypertension, macro-recorded together with documentation of any renal
symptoms. Physical examination included resting supine, scopic hematuria, urinary tract infection, and renal tract
calculi in ADPKD patients. From the results of the logis-and erect systolic and diastolic (phase V) blood pressure
measurements. The World Health Organization criteria tic regression analysis, the probability pi was calculated
for each patient to develop any of the four complicationsfor hypertension were used, and individuals were consid-
ered hypertensive if the systolic blood pressure was (i 5 1 . . . 4), given their age and sex. Based on the indi-
vidual presence (di 5 1) or absence (di 5 0) of each com-higher than 160 mm Hg or if the diastolic blood pressure
was higher than 95 mm Hg. Abdominal ultrasound was plication, a phenotypic score (S) was calculated for each
patient as S 5 Si 5 1 . . 4di · ln(pi) 2 (1 2 di) · ln(1 2 pi).arranged, and the presence and number of renal and
hepatic cysts were recorded. This score gives negative weight to the presence of com-
plications that are expected to be rare, given age and sex,Previously diagnosed. The medical history and cur-
rent renal symptoms of previously diagnosed individuals and positive weight to the absence of frequent complica-
tions. Thus, patients who are healthier than expected,were recorded, including age at diagnosis, the reasons
for diagnosis, and known complications of ADPKD, that based on the logistic regression results, have a higher phe-
notypic score. When insufficient information was availableis, hypertension requiring treatment, macrohematuria,
urinary tract infection, and urinary tract calculi. For mac- for all four complications, patients were excluded from
analysis. Families were allocated to mutational groupsroscopic hematuria, a history of passing urine with visible
blood was sufficient. Individuals were considered to have according to the location of their mutation in the cDNA
sequence, and mutation groups were numbered in as-suffered from urinary tract infection if, at any stage in
the past, they had been diagnosed or treated for cystitis, cending order (59 to 39). Families with identical muta-
tions were allocated to the same mutational group. Meanpyelonephritis, or cyst infection. A positive urine or
blood culture was not required for the diagnosis. For phenotypic scores were tested for statistically significant
differences between mutational groups by means of aurinary tract calculi, radiological evidence (ultrasound,
plain x-rays, intravenous pyelograms, computed tomog- multiple pair-wise t-test, as implemented in the General
Linear Model (GLM) procedure of SAS [24].raphy scans) was required. The age at onset of renal
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Table 1. PKD2 mutations characterized in 24 unrelated ADPKD families
Center Family Reference Mutation Exon Sequence change Codon change
Australia 8952a 2 1 556C.T R186X
13868 [18] 9 5 1240T.G W414G
15371 [18] 14 6 1480G.T E494X
Leiden 69 [18] 1 1 534-538insC Frameshift 180!212X
109a 18 10 2023-2024delAT Frameshift 675!681X
144 [18] 13 6 1445delT Frameshift 482!513X
147b 5 4 958C.T R320X
179 [18] 6 4 972-973insC Frameshift 325!340X
Bulgaria 7852 [18] 4 4 916C.T R306X
Santander 26 [18] 16 8 1717-3C.G Splice mutation
33 [18] 13 6 1445delT Frameshift 482!513X
34 [18] 11 6 1362-1363delTT Frameshift 455!460X
37 [18] 8 5 1194-1195delAA Frameshift 398!407X
London 02a 10 5 1249C.T R417X
Madrid 6017 [17] 15 7 1701-1704delTTTT Frameshift 567-582X
6019 [21] 19 11 2159delA Frameshift 720-736X
6030 [17] 21 13 2509G.T E837X
6075 [17] 12 6 1390C.T R464X
6090 [17] 20 13 2419C.T R807X
6113 [17] 3 2 667delG Frameshift 222-232X
Barcelona 21 [21] 10 5 1249C.T R417X
76 [21] 7 4 1066G.C A356P
85 [21] 17 8 1753C.T Q585X
113 [21] 22 13 2511AG.C Frameshift 837-843X
aPersonal communication, DM Peters, Leiden
bPersonal communication, S Somlo, New York
Table 2. Number of individuals who have died or reached end-stageRESULTS
renal disease (ESRD), with the mean age at death/ESRD
Fourteen PKD2 families from Spain, five from the
Mutational Mean age of death/Netherlands, three from Australia, one from the United group N Dead/ESRD ESRD
Kingdom, and one from Bulgaria were included in the
1 37 12 68
present study (Table 1). A total of 234 individuals af- 2 18 5 75
3 7 1 36fected by ADPKD (108 male and 126 female) was ana-
4 11 0 —lyzed, 165 (71%) of whom were alive and had not
5 15 8 62
reached ESRD at the time of study (Table 2). Twenty- 6 17 5 61
7 7 4 71two different mutations were identified in the 24 appar-
8 5 3 50ently unrelated families. A family from London shared
9 12 4 52
its C!T substitution at nucleotide 1249 with family Bar- 10 14 6 74
11 8 1 56celona 21, and family Leiden 144 had the same deletion
12 5 0 —of one thymidine at positions 1443 to 1445 as family
13 16 7 55
Santander 33. For 18 families, the respective PKD2 mu- 14 4 0 —
15 5 0 —tations have been previously reported [17, 18, 21]. Ten
16 13 3 62families had a nonsense mutation. Eleven had frame-
17 3 2 68
shifts. Two had a missense mutation, and one family had 18 7 2 82
19 8 1 69a splice mutation (Table 1). The mutations appeared
20 7 1 71to be evenly spread throughout the gene (from exon 1
21 8 1 69
through 13), without evidence for clustering or muta- 22 7 3 63
tional hot spots (Fig. 1).
As expected, logistic regression analysis revealed that
the probability of a history of hypertension, macroscopic
hematuria, renal calculi, and urinary tract infection in- correlation was observed between the age and pheno-
typic score for individuals who had died or reachedcreased with age (Table 3). A statistically significant sex
difference was only noted for urinary tract infection, ESRD (r 5 0.5407, P , 0.005). This observation lends
empiric support to the notion that the phenotypic scorehowever, with women being more frequently affected
than men. Phenotypic scores showed minimal variability defined previously in this article is a valid measure of
clinical severity in ADPKD.for individuals younger than 40 years of age but varied
considerably among older individuals (Fig. 2). A positive One-way analysis of variance (ANOVA) revealed that
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Fig. 1. Polycystin-2, the predicted protein product of the PKD2 gene. The locations of mutations are marked by arrows. The coil structures
located in exon 12 denote the calcium-binding EF hand domain. The coil-coiled domain that mediates the interaction between polycystin-1 and
-2 is located in exons 12 and 13.
Table 3. Logistic regression analysis of ADPKD vealed a significant difference in the mean phenotypic
associated complications
score between family Leiden 144 and family Santander
Age Sex 33 (t 5 3.276, P , 0.005), but not between the London
Complication x2 P x2 P family and family Barcelona 21 (t 5 1.204, 0.1 , P ,
0.2). No significant differences in phenotypic scores wereHypertension 40.10 0.0001 0.56 0.45
Macrohematuria 10.10 0.0015 1.71 0.19 found between the two groups of missense mutations or
Renal calculi 5.16 0.0231 0.15 0.70 between missense and truncating mutations (Table 4).
Urinary tract infections 10.12 0.0015 8.89 0.029
All x2 tests were performed with one d.f.
DISCUSSION
The present study has revealed that the location of
the disease-causing mutation within the PKD2 gene sig-the variability in phenotypic score was significantly higher
nificantly influences the clinical outcome. This findingbetween mutational groups than within groups (F 5 1.85,
has important implications for our understanding of the21 and 152 df, P 5 0.0018). The longitudinal pattern of
pathogenesis of ADPKD. Evidence has emerged for thevariability in phenotypic scores was nonlinear (Fig. 3),
so-called “two-hit hypothesis,” which proposes that cys-and further evidence for this assertion came from a
togenesis requires a somatic mutation (second hit) ingroup-wise comparison of mean phenotypic scores, using
addition to a germline mutation (first hit) [25–27]. Ata multiple t-test (Table 4). Mutational groups character-
the PKD1 locus, loss of heterozygosity (LOH) has beenized by significantly different high and low scores were
demonstrated in a subset of cysts in epithelial cells, withinterspersed along the gene sequence. A pair-wise com-
parison of the families sharing identical mutations re- the wild-type copy of the gene being lost. The second-
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Fig. 2. Age versus phenotypic score in PKD2
patients. Symbols are: (h) living patients who
have not reached end-stage renal disease
(ESRD); (n) patients who have died or
reached ESRD.
Fig. 3. Scatterplot of phenotypic scores in 22
mutational groups, ordered according to their
location in the PKD2 cDNA sequence.
hit hypothesis for PKD1-associated disease is also sup- velop polycystic kidney disease. Cyst formation is more
common in heterozygote knockout mice than in miceported by immunolocalization studies, which reveal a
heterogeneous pattern, with 20 to 30% of cysts containing heterozygote for the unstable allele, since the latter must
undergo rearrangement of the unstable allele as well.no detectable polycystin-1 and other cysts demonstrating
apparent overexpression of polycystin-1 [28, 29]. It has Homozygous knockout mouse embryos exhibit a com-
plete absence of PKD2 protein and are not viable. Thesebeen suggested that the overexpression of polycystin-1
may be due to an accumulation of an abnormal protein or reports suggest that both PKD1 and PKD2 occur as the
result of cellular recessive mechanisms.may reflect enhanced expression associated with cellular
dedifferentiation [30]. Recently, the introduction of a Our findings, however, suggest that some PKD2 germ-
line mutations might not result in a simple loss of proteinmutant exon 1 creating an unstable allele at the mouse
PKD2 locus was described that resulted in somatic inacti- function. It is possible that this also holds true for the
second somatic PKD2 hit responsible for cystogenesisvation [27]. Mice heterozygous or homozygous for this
mutation, as well as heterozygous knockout mice, de- and that the phenomenon also occurs in PKD1. The
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Table 4. Mean phenotypic scores and standard deviations of PKD2 the concept that polycystin-2 has several functional do-
patients by mutational group
mains.
Mutation Exon N Mean score Standard deviation The large majority of mutations described in the pres-
1 1 26 0.127ab 1.682 ent study, as well as in previous reports, are nonsense
2 1 14 21.005abcd 2.392 mutations and frameshifts resulting in premature transla-
3 2 6 0.175ab 0.931
tion stops. Mutations at the 39 end of the gene, occurring4 4 11 22.046bcd 2.848
5 4 7 0.082ab 0.798 after the EF-hand domain and the coil-coiled domain,
6 4 11 20.090ab 1.787 have relatively high phenotypic scores, indicating that
7e 4 2 20.821abcd 1.720
patients in these groups are clinically less severely af-8 5 3 0.407a 0.620
9e 5 8 21.194abcd 1.920 fected (Fig. 3). This suggests that a truncated polycystin-2
10 5 11 20.144ab 1.285 with only a small section of its C terminus missing may
11 5 8 0.616a 1.100
retain a significant degree of function. Although the pat-12 6 4 0.400a 0.285
13 6 14 20.803abcd 2.327 tern of phenotypic scores along the cDNA sequence is
14 6 4 0.138ab 0.533 nonlinear, mutations in the first few exons result in compar-
15 7 5 20.427abc 1.450
atively low scores, whereas mutations in exons 6 through16 8 11 0.630a 0.340
17 8 1 22.777d 0.000 8 cause intermediate severity. It would indeed seem un-
18 10 5 22.717cd 4.386 likely that truncating mutations occurring very early in
19 11 5 20.438abc 1.697
the gene sequence would result in sufficient amounts of20 13 6 0.336a 0.418
21 13 8 0.655a 0.402 functional product. A correlation between phenotypic
22 13 4 0.312a 0.387 severity and the amount of functional protein present has
a,b,c,dMean scores marked by nonoverlapping sets of letters were found to differ been observed for other conditions, such as, for example,
significantly in a multiple pairwise t-test (overall P , 0.05)
Duchenne/Becker muscular dystrophy. Patients with aeMissense mutations
small but functional dystrophin product, caused by dele-
tions that leave the reading frame intact, are usually
affected by the comparatively mild Becker phenotype.
observation that clinical severity is influenced by the In contrast, premature truncation of dystrophin caused
location of the mutation within the PKD2 gene implies by deletions that disrupt the reading frame is associated
that, at least in some patients, the mutant polycystin-2 with a severe Duchenne phenotype [34].
The present genotype-phenotype analysis was basedmust have some residual function. A similar phenome-
on four frequent and clinically prominent complications:non may be occurring in PKD1, a hypothesis that is
hypertension, macroscopic hematuria, urinary tract in-supported by recent recognition of significant variability
fection, and renal calculi. The association of these com-of phenotype among large PKD1 families with different
plications with ADPKD is well established [35], althoughdisease-associated haplotypes [31].
these data most likely pertain to PKD1-related disease.As yet, very little is known about the function of poly-
Several groups have reported a milder phenotype forcystin-2, which is predicted to be a 968 amino acid inte-
PKD2 as compared with PKD1 [14, 36, 37], and thisgral membrane protein with six transmembrane domains
finding was recently confirmed in a large multicenterand two intracellular tails (Fig. 1). There is an approxi-
study [15]. Nevertheless, most complications are respon-mately 25% identity and an approximately 50% similar-
sible for significant morbidity in both forms of ADPKD.ity between polycystin-2 and a region of 450 amino acids
Setting aside ESRD, the complications chosen here toof polycystin-1, the product of the PKD1 gene [7]. Poly-
assess phenotypic severity are among the clinically mostcystin-1 is a 4302 amino acid integral membrane protein
prominent aspects of ADPKD. While the relative contri-
with a large extracellular region and 11 predicted trans-
bution of these complications to the clinical severity of
membrane domains; it is thought to act in cell–cell or ADPKD remains unclear, our observation of a positive
cell–matrix interactions [4–6]. Polycystin-1 and polycystin-2 correlation between age and phenotypic score among
interact via coil-coiled domains in their C-terminal cyto- older individuals, particularly those who had died or
plasmic tails in vitro, suggesting that PKD1 and PKD2 reached ESRD, lends empiric support to the notion that
may function through a common signaling pathway [32, the phenotypic score based on these complications is a
33]. Polycystin-2 has an EF-hand domain at the C termi- valid measure of clinical severity in ADPKD. An attempt
nus, which can be involved in the binding of calcium and was also made to assess for differences between muta-
also shows homology to the family of voltage-activated tional groups using survival to ESRD or death as end-
calcium (and sodium) channel proteins, suggesting that points. This proved not to be feasible because, as a result
it may function as an ion channel [7]. Our observation of the overall milder phenotype of PKD2, there were
of phenotypic differences between families with different insufficient endpoints available for statistical analysis.
Although information about other clinical problems suchPKD2 mutations provides clinical evidence to support
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as hernia and subarachnoid hemorrhage was also col- to induce cystogenesis, and the pathophysiology of the
clonal proliferation of the resultant cyst may be depen-lected, again, the prevalence figures obtained were too
small to allow meaningful statistical analysis. dent on the nature and location of the second-hit muta-
tion. To clarify this issue and to improve our understand-We assessed clinical data from families with 22 differ-
ent PKD2 mutations and have demonstrated statistically ing of ADPKD further, additional functional studies of
normal and mutant polycystin-1 and polycystin-2 are re-significant differences in clinical expression between a
number of the mutational groups. A degree of intrafam- quired.
ily variability was also observed. The nature and fre-
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